

# Abstract 955: Oncology Trial Enrollment Trends Following the First Wave of the

Elizabeth Lamont, MD, MS<sup>1</sup> | Kevin Blum, MS<sup>1</sup> | Ron Katriel, PhD<sup>1</sup> | Lisa Ensign, PhD<sup>1</sup>

<sup>1</sup> Medidata Acorn AI, a Dassault Systèmes company, New York, NY, 10014

## BACKGROUND

- The COVID-19 pandemic has disrupted healthcare delivery including clinical research & development
- Prior reports suggest the initial pandemic wave caused a 60% drop in new oncology trials & slowed patient enrollment in oncology trials by a similar magnitude<sup>1,2</sup>
- Did the pandemic continue to hinder clinical research and development in oncology beyond its first wave?

## METHODS

## CONCLUSIONS

- COVID-19 pandemic had its maximal negative effect on 2020 global oncology trial enrollment in period 1 (i.e., first wave)
- A subsequent surge in trial enrollment in period 3 largely offset the effect with cumulative enrollment in 2020 similar to 2018 and 2019


## FUTURE DIRECTIONS FOR RESEARCH

- Ongoing research is directed at identifying and quantifying the adaptive mechanisms which facilitated the stunning enrollment rebound

### References:

1. Lamont EB, Diamond SS, Katriel RG, et al. Trends in oncology clinical trials launched before and during the COVID-19 pandemic. *JAMA Netw Open*. 2021;4(1):e2036353.
2. Tolane SM, Lydon CA, Li T, et al. The impact of COVID-19 on clinical trial execution at Dana-Farber Cancer Institute. *J Natl Cancer Inst*. 2020;113(11):dja1144.
3. European Centre for Disease Prevention and Control. Data provided subject to license available at: <https://www.ecdc.europa.eu/en/copyright>

## RESULTS



**Oncology trial enrollments surge after first COVID-19 shock, puts 2020 patient enrollment on par with 2018 and 2019**